From the Guidelines
The Prenosis Sepsis ImmunoScore should be used as a diagnostic aid to help clinicians identify sepsis earlier and predict which patients are at highest risk for rapid deterioration within 24 hours, as early identification and intervention can significantly improve outcomes and reduce mortality rates associated with sepsis. The ImmunoScore analyzes various biomarkers and patient data to generate a risk score, allowing for more timely intervention in high-risk patients. When using the ImmunoScore, clinicians should integrate the results with their clinical assessment rather than relying solely on the AI prediction, as recommended by the Surviving Sepsis Campaign guidelines 1. The test is particularly valuable in emergency departments and ICUs where early identification of sepsis can significantly improve outcomes.
Some key points to consider when using the ImmunoScore include:
- Early identification of sepsis is critical to improving outcomes, as delayed diagnosis and treatment can lead to increased morbidity and mortality 1
- The ImmunoScore can help clinicians identify patients at high risk for rapid deterioration, allowing for earlier intervention and potentially improving outcomes
- The test should be used in conjunction with clinical assessment and other diagnostic tools, rather than relying solely on the AI prediction
- Early antibiotic administration, fluid resuscitation, and other interventions can be critical in preventing the progression of sepsis to severe sepsis or septic shock, and the ImmunoScore can help clinicians prioritize these interventions in high-risk patients 1
Overall, the Prenosis Sepsis ImmunoScore has the potential to significantly improve sepsis care by providing an early warning system for clinicians to identify high-risk patients and intervene earlier, potentially reducing mortality rates associated with this life-threatening condition.
From the Research
Prenosis Sepsis ImmunoScore Overview
- The Prenosis Sepsis ImmunoScore is an AI diagnostic test for sepsis that helps doctors diagnose infections and predict which patients are most likely to progress quickly with severe cases within the next 24 hours.
- However, there is no direct evidence in the provided studies to support the effectiveness of the Prenosis Sepsis ImmunoScore.
Treatment of Sepsis
- The provided studies focus on the treatment of sepsis using antibiotics such as meropenem and piperacillin-tazobactam 2, 3, 4, 5, 6.
- Meropenem has been shown to have a lower mortality rate compared to piperacillin-tazobactam in some studies 2, 5.
- Continuous infusion of meropenem has been found to be superior to intermittent infusion in terms of mortality, clinical cure rate, and microbiological eradication 5.
Antibiotic Resistance
- The studies also highlight the issue of antibiotic resistance, particularly in gram-negative bacteria 4, 6.
- Prior antibiotic use, nursing home residence, and transfer from an outside hospital have been associated with resistance to antibiotics such as meropenem and piperacillin-tazobactam 4.
- Clinical decision trees can be used to distinguish patients at low, intermediate, or high risk of resistance to certain antibiotics 4.
Clinical Trials
- Several clinical trials have been conducted to compare the effectiveness of different antibiotics in the treatment of sepsis, including the MERINO trial 6 and the EMPRESS trial 3.
- These trials aim to provide evidence for the safety and efficacy of different treatment options and to inform clinical practice.